{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T14:30:39Z","timestamp":1794234639730,"version":"4.9.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["No. 2021YFH0187"],"award-info":[{"award-number":["No. 2021YFH0187"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["No. 2018HH0062"],"award-info":[{"award-number":["No. 2018HH0062"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>For chronic hepatitis B virus (HBV) infection patients, increasing evidence has demonstrated the effectiveness of expanding the indications and applicable population for antiviral therapy. However, the expanded indication of antiviral therapy for hepatocellular carcinoma (HCC) remains to be further explored.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>196 HBV-related HCC patients who received radical hepatectomy and nucleos(t)ide analogues (NAs) therapy at Sichuan Provincial People\u2019s Hospital were enrolled in this study. HCC recurrence, overall survival (OS), early virological (VR) and biochemical responses (BR) of patients were compared between different NAs therapy and the use of anti-programmed cell death protein 1 (PD-1) therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>NAs therapy at different timing of surgery was a strong independent risk factor for postoperative recurrence and overall mortality of HBV-related HCC patients. Furthermore, in HCC patients who received postoperative anti-PD-1 therapy, patients with HBV DNA\u2009&lt;\u20091000 copy\/mL had significantly better recurrence-free survival (RFS) and OS than those with HBV DNA\u2009\u2265\u20091000 copy\/mL (HR: 7.783; P\u2009=\u20090.002; HR: 6.699; P\u2009&lt;\u20090.001). However, the differences of RFS and OS rates between entecavir group and tenofovir disoproxil fumarate group were not statistically significant. Similar results were also observed in the rates of early VR, BR and combined VR and BR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Timely and reasonable preoperative NAs therapy showed clinical benefit in improving the prognosis of patients with HBV-related HCC, even in the case of normal alanine aminotransferase (ALT) level and negative hepatitis e antigen (HBeAg). Furthermore, a possible synergistic effect between antiviral therapy and anti-PD-1 therapy was founded and need further verification.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-12031-0","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T15:01:46Z","timestamp":1709564506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Impact of preoperative antiviral therapy on the prognosis of hepatitis B virus-related hepatocellular carcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Yuxin","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyou","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"issue":"3","key":"12031_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"10","key":"12031_CR2","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1111\/liv.14607","volume":"40","author":"W Li","year":"2020","unstructured":"Li W, Deng R, Liu S, Wang K, Sun J. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: the emerging role of non-viral risk factors. Liver International: Official J Int Association Study Liver. 2020;40(10):2316\u201325.","journal-title":"Liver International: Official J Int Association Study Liver"},{"issue":"2","key":"12031_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. Cancer J Clin. 2016;66(2):115\u201332.","journal-title":"Cancer J Clin"},{"issue":"4","key":"12031_CR4","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","volume":"56","author":"EASL-EORTC clinical","year":"2012","unstructured":"EASL-EORTC clinical. Practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908\u201343.","journal-title":"J Hepatol"},{"issue":"3","key":"12031_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/00000658-200203000-00009","volume":"235","author":"RT Poon","year":"2002","unstructured":"Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235(3):373\u201382.","journal-title":"Ann Surg"},{"issue":"1","key":"12031_CR6","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore MD). 2018;67(1):358\u201380.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"2","key":"12031_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11684-021-0848-3","volume":"15","author":"W Zhang","year":"2021","unstructured":"Zhang W, Zhang B, Chen XP. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front Med. 2021;15(2):155\u201369.","journal-title":"Front Med"},{"issue":"18","key":"12031_CR8","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/2012.jama.11975","volume":"308","author":"CY Wu","year":"2012","unstructured":"Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT. Association between nucleoside analogues and risk of hepatitis B virus\u2013related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012;308(18):1906\u201314.","journal-title":"JAMA"},{"issue":"3","key":"12031_CR9","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","volume":"130","author":"UH Iloeje","year":"2006","unstructured":"Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678\u201386.","journal-title":"Gastroenterology"},{"key":"12031_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejim.2021.02.019","volume":"89","author":"JH Lee","year":"2021","unstructured":"Lee JH, Kim BK, Park SY, Tak WY, Park JY, Kim DY, Ahn SH, Sinn DH, Kim SU. The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma. Eur J Intern Med. 2021;89:48\u201355.","journal-title":"Eur J Intern Med"},{"issue":"29","key":"12031_CR11","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1200\/JCO.2012.48.5896","volume":"31","author":"J Yin","year":"2013","unstructured":"Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, Guo W, Zhang H, Wang H, Cheng S, et al. Effect of antiviral treatment with nucleotide\/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncology: Official J Am Soc Clin Oncol. 2013;31(29):3647\u201355.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"1","key":"12031_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/SLA.0000000000000858","volume":"261","author":"G Huang","year":"2015","unstructured":"Huang G, Lau WY, Wang ZG, Pan ZY, Yuan SX, Shen F, Zhou WP, Wu MC. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg. 2015;261(1):56\u201366.","journal-title":"Ann Surg"},{"issue":"7","key":"12031_CR13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/apt.13548","volume":"43","author":"GL Wong","year":"2016","unstructured":"Wong GL, Tse YK, Chan HL, Yip TC, Tsoi KK, Wong VW. Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2016;43(7):802\u201313.","journal-title":"Aliment Pharmacol Ther"},{"key":"12031_CR14","doi-asserted-by":"crossref","unstructured":"EASL. 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of hepatology 2017, 67(2):370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"issue":"1","key":"12031_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, et al. Asian-pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hep Intl. 2016;10(1):1\u201398.","journal-title":"Hep Intl"},{"issue":"1","key":"12031_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/cld.728","volume":"12","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr., Bzowej NH, Wong JB. Update on Prevention, diagnosis, and treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Clin Liver Disease. 2018;12(1):33\u20134.","journal-title":"Clin Liver Disease"},{"issue":"1","key":"12031_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","volume":"5","author":"J Choi","year":"2019","unstructured":"Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim YS. Risk of Hepatocellular Carcinoma in patients treated with Entecavir vs Tenofovir for Chronic Hepatitis B: a Korean Nationwide Cohort Study. JAMA Oncol. 2019;5(1):30\u20136.","journal-title":"JAMA Oncol"},{"issue":"2","key":"12031_CR18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.31289","volume":"73","author":"J Choi","year":"2021","unstructured":"Choi J, Jo C, Lim YS. Tenofovir Versus Entecavir on recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection. Hepatology (Baltimore MD). 2021;73(2):661\u201373.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"3","key":"12031_CR19","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jhep.2019.03.028","volume":"71","author":"SU Kim","year":"2019","unstructured":"Kim SU, Seo YS, Lee HA, Kim MN, Lee YR, Lee HW, Park JY, Kim DY, Ahn SH, Han KH, et al. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-na\u00efve chronic hepatitis B in South Korea. J Hepatol. 2019;71(3):456\u201364.","journal-title":"J Hepatol"},{"issue":"7","key":"12031_CR20","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1136\/gutjnl-2019-318947","volume":"69","author":"SW Lee","year":"2020","unstructured":"Lee SW, Kwon JH, Lee HL, Yoo SH, Nam HC, Sung PS, Nam SW, Bae SH, Choi JY, Yoon SK, et al. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-na\u00efve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut. 2020;69(7):1301\u20138.","journal-title":"Gut"},{"issue":"5","key":"12031_CR21","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/hep.29320","volume":"66","author":"GV Papatheodoridis","year":"2017","unstructured":"Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in caucasians with chronic hepatitis B. Hepatology (Baltimore MD). 2017;66(5):1444\u201353.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"4","key":"12031_CR22","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/hep.22476","volume":"48","author":"MJ Tong","year":"2008","unstructured":"Tong MJ, Hsien C, Hsu L, Sun HE, Blatt LM. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology (Baltimore MD). 2008;48(4):1070\u20138.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"12","key":"12031_CR23","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/jvh.13185","volume":"26","author":"DH Sinn","year":"2019","unstructured":"Sinn DH, Kim SE, Kim BK, Kim JH, Choi MS. The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria. J Viral Hepatitis. 2019;26(12):1465\u201372.","journal-title":"J Viral Hepatitis"},{"issue":"4","key":"12031_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.21037\/hbsn-20-480","volume":"9","author":"DY Xie","year":"2020","unstructured":"Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452\u201363.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"12","key":"12031_CR25","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A, Keam SJ. Camrelizumab: First Global approval. Drugs. 2019;79(12):1355\u201361.","journal-title":"Drugs"},{"issue":"3","key":"12031_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00535-022-01855-x","volume":"57","author":"XH Wang","year":"2022","unstructured":"Wang XH, Hu ZL, Fu YZ, Hou JY, Li WX, Zhang YJ, Xu L, Zhou QF, Chen MS, Zhou ZG. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection. J Gastroenterol. 2022;57(3):185\u201398.","journal-title":"J Gastroenterol"},{"issue":"1","key":"12031_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4097\/kja.21209","volume":"75","author":"FS Nahm","year":"2022","unstructured":"Nahm FS. Receiver operating characteristic curve: overview and practical use for clinicians. Korean J Anesthesiology. 2022;75(1):25\u201336.","journal-title":"Korean J Anesthesiology"},{"issue":"1","key":"12031_CR28","doi-asserted-by":"publisher","first-page":"101821","DOI":"10.1016\/j.semerg.2022.101821","volume":"49","author":"JA Mart\u00ednez P\u00e9rez","year":"2023","unstructured":"Mart\u00ednez P\u00e9rez JA. P\u00e9rez Martin PS: [ROC curve]. Semergen. 2023;49(1):101821.","journal-title":"Semergen"},{"issue":"4","key":"12031_CR29","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1478-3231.2008.01957.x","volume":"29","author":"P Tandon","year":"2009","unstructured":"Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver International: Official J Int Association Study Liver. 2009;29(4):502\u201310.","journal-title":"Liver International: Official J Int Association Study Liver"},{"issue":"8","key":"12031_CR30","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ejso.2012.04.010","volume":"38","author":"T Yang","year":"2012","unstructured":"Yang T, Lu JH, Zhai J, Lin C, Yang GS, Zhao RH, Shen F, Wu MC. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol. 2012;38(8):683\u201391.","journal-title":"Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol"},{"issue":"7","key":"12031_CR31","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1111\/j.1572-0241.2008.01872.x","volume":"103","author":"IF Hung","year":"2008","unstructured":"Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol. 2008;103(7):1663\u201373.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"12031_CR32","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/SLA.0000000000002727","volume":"268","author":"G Huang","year":"2018","unstructured":"Huang G, Li PP, Lau WY, Pan ZY, Zhao LH, Wang ZG, Wang MC, Zhou WP. Antiviral therapy reduces Hepatocellular Carcinoma recurrence in patients with low HBV-DNA levels: a Randomized Controlled Trial. Ann Surg. 2018;268(6):943\u201354.","journal-title":"Ann Surg"},{"issue":"5","key":"12031_CR33","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","volume":"142","author":"TC Tseng","year":"2012","unstructured":"Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142(5):1140\u20139. e1143; quiz e1113-1144.","journal-title":"Gastroenterology"},{"issue":"1","key":"12031_CR34","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12885-017-3293-6","volume":"17","author":"X Wei","year":"2017","unstructured":"Wei X, Li N, Li S, Shi J, Guo W, Zheng Y, Cheng S. Hepatitis B virus infection and active replication promote the formation of vascular invasion in hepatocellular carcinoma. BMC Cancer. 2017;17(1):304.","journal-title":"BMC Cancer"},{"key":"12031_CR35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13027-019-0219-8","volume":"14","author":"C Qu","year":"2019","unstructured":"Qu C, Huang X, Liu K, Li K, Tan B, Qu L, Cao J, Zhu C. Effect of hepatitis B virus DNA replication level and anti-HBV therapy on microvascular invasion of hepatocellular carcinoma. Infect Agents cancer. 2019;14:2.","journal-title":"Infect Agents cancer"},{"issue":"10","key":"12031_CR36","doi-asserted-by":"publisher","first-page":"e182721","DOI":"10.1001\/jamasurg.2018.2721","volume":"153","author":"Z Li","year":"2018","unstructured":"Li Z, Lei Z, Xia Y, Li J, Wang K, Zhang H, Wan X, Yang T, Zhou W, Wu M, et al. Association of Preoperative Antiviral Treatment with incidences of Microvascular Invasion and Early Tumor recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma. JAMA Surg. 2018;153(10):e182721.","journal-title":"JAMA Surg"},{"key":"12031_CR37","doi-asserted-by":"crossref","unstructured":"Macek Jilkova Z, Aspord C, Decaens T. Predictive factors for response to PD-1\/PD-L1 checkpoint inhibition in the field of Hepatocellular Carcinoma: current Status and challenges. Cancers 2019, 11(10).","DOI":"10.3390\/cancers11101554"},{"issue":"5","key":"12031_CR38","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/hep.27246","volume":"60","author":"T Hato","year":"2014","unstructured":"Hato T, Goyal L, Greten TF, Duda DG, Zhu AX. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology (Baltimore MD). 2014;60(5):1776\u201382.","journal-title":"Hepatology (Baltimore MD)"},{"key":"12031_CR39","doi-asserted-by":"publisher","first-page":"104992","DOI":"10.1016\/j.phrs.2020.104992","volume":"159","author":"L Jia","year":"2020","unstructured":"Jia L, Gao Y, He Y, Hooper JD, Yang P. HBV induced hepatocellular carcinoma and related potential immunotherapy. Pharmacol Res. 2020;159:104992.","journal-title":"Pharmacol Res"},{"issue":"3","key":"12031_CR40","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/nsr\/nwu038","volume":"1","author":"P Yang","year":"2014","unstructured":"Yang P, Markowitz GJ, Wang XF. The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma. Natl Sci Rev. 2014;1(3):396\u2013412.","journal-title":"Natl Sci Rev"},{"key":"12031_CR41","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.3389\/fimmu.2019.02048","volume":"10","author":"Y Chen","year":"2019","unstructured":"Chen Y, Tian Z. HBV-Induced Immune Imbalance in the development of HCC. Front Immunol. 2019;10:2048.","journal-title":"Front Immunol"},{"issue":"5","key":"12031_CR42","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/gutjnl-2018-316510","volume":"68","author":"CJ Lim","year":"2019","unstructured":"Lim CJ, Lee YH, Pan L, Lai L, Chua C, Wasser M, Lim TKH, Yeong J, Toh HC, Lee SY, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2019;68(5):916\u201327.","journal-title":"Gut"},{"issue":"6","key":"12031_CR43","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1084\/jem.20162115","volume":"214","author":"LJ Pallett","year":"2017","unstructured":"Pallett LJ, Davies J, Colbeck EJ, Robertson F, Hansi N, Easom NJW, Burton AR, Stegmann KA, Schurich A, Swadling L, et al. IL-2(high) tissue-resident T cells in the human liver: sentinels for hepatotropic infection. J Exp Med. 2017;214(6):1567\u201380.","journal-title":"J Exp Med"},{"issue":"2","key":"12031_CR44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/apt.13034","volume":"41","author":"CC Chong","year":"2015","unstructured":"Chong CC, Wong GL, Wong VW, Ip PC, Cheung YS, Wong J, Lee KF, Lai PB, Chan HL. Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. Aliment Pharmacol Ther. 2015;41(2):199\u2013208.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"12031_CR45","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/j.1365-2036.2011.04634.x","volume":"33","author":"JS Wong","year":"2011","unstructured":"Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong CN, Wong J, Lee KF, Lai PB, Chan HL. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2011;33(10):1104\u201312.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"12031_CR46","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/liv.12112","volume":"33","author":"XM Lao","year":"2013","unstructured":"Lao XM, Luo G, Ye LT, Luo C, Shi M, Wang D, Guo R, Chen M, Li S, Lin X, et al. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver International: Official J Int Association Study Liver. 2013;33(4):595\u2013604.","journal-title":"Liver International: Official J Int Association Study Liver"},{"issue":"6","key":"12031_CR47","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/jvh.12855","volume":"25","author":"H Cho","year":"2018","unstructured":"Cho H, Ahn H, Lee DH, Lee JH, Jung YJ, Chang Y, Nam JY, Cho YY, Lee DH, Cho EJ, et al. Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals. J Viral Hepatitis. 2018;25(6):707\u201317.","journal-title":"J Viral Hepatitis"},{"key":"12031_CR48","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13027-018-0191-8","volume":"13","author":"M Zhang","year":"2018","unstructured":"Zhang M, Wang D, Liu H, Li H. Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection. Infect Agents cancer. 2018;13:19.","journal-title":"Infect Agents cancer"},{"issue":"2","key":"12031_CR49","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/gutjnl-2016-312653","volume":"67","author":"K Murata","year":"2018","unstructured":"Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E, Inoue T, Sakamoto M, Enomoto N, Shirasaki T, et al. Induction of IFN-\u03bb3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut. 2018;67(2):362\u201371.","journal-title":"Gut"},{"issue":"5","key":"12031_CR50","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1002\/hep.30956","volume":"71","author":"K Murata","year":"2020","unstructured":"Murata K, Tsukuda S, Suizu F, Kimura A, Sugiyama M, Watashi K, Noguchi M, Mizokami M. Immunomodulatory mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus infection. Hepatology (Baltimore MD). 2020;71(5):1533\u201345.","journal-title":"Hepatology (Baltimore MD)"},{"key":"12031_CR51","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fimmu.2017.00119","volume":"8","author":"M Syedbasha","year":"2017","unstructured":"Syedbasha M, Egli A. Interferon Lambda: modulating immunity in Infectious diseases. Front Immunol. 2017;8:119.","journal-title":"Front Immunol"}],"updated-by":[{"DOI":"10.1186\/s12885-024-12108-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12031-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12031-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12031-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T10:05:10Z","timestamp":1710497110000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12031-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12031"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12031-0","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12885-024-12108-w","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]},"assertion":[{"value":"10 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12885-024-12108-w","URL":"https:\/\/doi.org\/10.1186\/s12885-024-12108-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental protocol was established, according to the ethical guidelines of the Helsinki Declaration and was approved by the Human Ethics Committee of Sichuan Academy of Medical Sciences & Sichuan Provincial People\u2019s Hospital (NO.2023030). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"291"}}